Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Vials: $349 (2.5 mg), $499 (5 mg, 7.5 mg, 10 mg) Mounjaro: $1,080, people lost an average of 21% of body weight at 72 weeks
The consolidated cases in MDL 3094 include claims involving multiple GLP-1 receptor agonist medications: Ozempic and Wegovy (semaglutide) manufactured by Novo Nordisk Rybelsus (oral semaglutide) manufactured by Novo Nordisk Mounjaro (tirzepatide) manufactured by Eli Lilly Trulicity (dulaglutide) manufactured by Eli Lilly Saxenda (liraglutide) recently added to the MDL in December 2024 Unlike a traditional class action where all plaintiffs receive identical settlements, the MDL process for Ozempic cases allows for individualized compensation based on injury severity, duration of use, and specific damages incurred
Fibre increases satiety, slows digestion, and helps regulate blood glucose levelseffects that complement semaglutide's appetite-suppressing mechanisms
Every body responds differently
US$ 29.31
US$ 29.88
US$ 21.98
US$ 29.74
US$ 22.47
US$ 29.89
US$ 22.22
US$ 29.81
